Example scenarios

You can try new scenarios by modifying any of the ones below.

1. Single dose of warfarin.
   1. 10mg in a CYP2C9*1*1 simulated 70kg subject
      (S)-warfarin is cleared faster than (R)-warfarin.
   2. 10mg in a CYP2C9*1*1 simulated 120kg subject
   3. 10mg in a CYP2C9*1*1 simulated 50kg subject
   4. 10mg in a CYP2C9*1*2 simulated 70kg subject
   5. 10mg in a CYP2C9*1*3 simulated 70kg subject
      (S)-warfarin is cleared slower than (R)-warfarin.
2. Loading with acenocoumarol.
   1. 4-4-4 mg of acenocoumarol in a CYP2C9*1*1 simulated 70kg subject
   2. 4-4-4 mg of acenocoumarol in a CYP2C9*1*1 simulated subject weighting 120kg
   3. 4-4-4 mg of acenocoumarol in a CYP2C9*1*1 simulated subject weighting 50kg
   4. 4-4-4 mg of acenocoumarol in a CYP2C9*1*2 simulated 70kg subject
   5. 4-4-4 mg of acenocoumarol in a CYP2C9*1*3 simulated 70kg subject
   6. 4-4-4 mg of acenocoumarol in a CYP2C9*3*3 simulated 70kg subject
3. Loading and maintenance with acenocoumarol. The effect of multiple day schemes on the stability of the INR.
   1. 4-4-4 mg loading, then maintenance with the ideal daily dose of 2.44mg in a 70kg CYP2C9*1*1 simulated subject
      INR range of variation is about 0.3.
   2. 4-4-4 mg loading, then maintenance with a 2mg-3mg schedule in a 70kg CYP2C9*1*1 simulated subject
      INR range of variation is about 0.5.
   3. 4-4-4 mg loading, then maintenance with a 2mg-2mg-2mg-1mg schedule in a 80kg CYP2C9*1*3 simulated subject
      INR range of variation is about 1.0.
4. Reproduction of published cases and data.
   1. Propositus (CYP2C9*1*3) subject from [Thijssen & al., 2001]
   2. Single administration of 8mg acenocoumarol in the same case. Blood concentrations of R and S acenocoumarol are supposed to approximate the evolution from [Thijssen & al., 2001] figure 2(A)
   3. Single administration of 8mg acenocoumarol in a CYP2C9*1*1 subject. Blood concentrations of R and S acenocoumarol are supposed to approximate the evolution from [Thijssen & al., 2001] figure 2(B)
   4. The effect of administering in a 70kg CYP2C9*1*1 subject the regimen from [D'Angelo & al., 2002].

^*We will only use your e-mail address to answer your message.